

Simona Gallo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1150979/publications.pdf>

Version: 2024-02-01

15
papers

495
citations

1040056

9
h-index

996975

15
g-index

15
all docs

15
docs citations

15
times ranked

910
citing authors

#	ARTICLE	IF	CITATIONS
1	ERK: A Key Player in the Pathophysiology of Cardiac Hypertrophy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2164.	4.1	168
2	Cellular and molecular mechanisms of HGF/Met in the cardiovascular system. <i>Clinical Science</i> , 2015, 129, 1173-1193.	4.3	112
3	HGF and MET: From Brain Development to Neurological Disorders. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 683609.	3.7	47
4	Signaling to Cardiac Hypertrophy: Insights from Human and Mouse RASopathies. <i>Molecular Medicine</i> , 2012, 18, 938-947.	4.4	39
5	HGF/Met Axis in Heart Function and Cardioprotection. <i>Biomedicines</i> , 2014, 2, 247-262.	3.2	32
6	Identification of novel circulating microRNAs in advanced heart failure by next-generation sequencing. <i>ESC Heart Failure</i> , 2021, 8, 2907-2919.	3.1	22
7	Activation of the MET receptor attenuates doxorubicin-induced cardiotoxicity in vivo and in vitro. <i>British Journal of Pharmacology</i> , 2020, 177, 3107-3122.	5.4	20
8	Gene expression profiling of HGF/Met activation in neonatal mouse heart. <i>Transgenic Research</i> , 2013, 22, 579-593.	2.4	12
9	Cardiac concentric hypertrophy promoted by activated Met receptor is mitigated in vivo by inhibition of Erk1,2 signalling with Pimasertib. <i>Journal of Molecular and Cellular Cardiology</i> , 2016, 93, 84-97.	1.9	12
10	A New Transgenic Mouse Model of Heart Failure and Cardiac Cachexia Raised by Sustained Activation of Met Tyrosine Kinase in the Heart. <i>BioMed Research International</i> , 2016, 2016, 1-13.	1.9	10
11	A mouse model for spatial and temporal expression of HGF in the heart. <i>Transgenic Research</i> , 2011, 20, 1203-1216.	2.4	8
12	The Long-Lasting Protective Effect of HGF in Cardiomyoblasts Exposed to Doxorubicin Requires a Positive Feed-Forward Loop Mediated by Erk1,2-Timp1-Stat3. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5258.	4.1	5
13	Anti-Differentiation Effect of Oncogenic Met Receptor in Terminally-Differentiated Myotubes. <i>Biomedicines</i> , 2015, 3, 124-137.	3.2	3
14	Molecular Engineering Strategies Tailoring the Apoptotic Response to a MET Therapeutic Antibody. <i>Cancers</i> , 2020, 12, 741.	3.7	3
15	Engineering, Characterization, and Biological Evaluation of an Antibody Targeting the HGF Receptor. <i>Frontiers in Immunology</i> , 2021, 12, 775151.	4.8	2